Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer |
| |
| Authors: | Zhou Zheng-tao Zhou Fu-xiang Wei Qing Zou Li-yong Qin Bin-fang Peng Xu-shen |
| |
| Affiliation: | (1) Department of Medical and Radiation Oncology, Zhongnan Hospital of Wuhan University, 430071 Wuhan, China;(2) Department of Oncology, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People’s Hospital, 443003 Yichang, China;(3) Department of Pharmacy, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People’s Hospital, 443003 Yichang, China;(4) Department of Oncology, The Second Hospital of Yichang, 443000 Yichang, China; |
| |
| Abstract: | ![]()
Purpose To investigate the efficacy and safety of endostar, a novel recombinant human endostatin, plus cisplatin, and etoposide in patients with extensive-stage small-cell lung cancer (ED-SCLC). |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
